MR Antagonist and LSD1
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT04840342
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT04840342
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04840342. Randomized; triple masking; primary purpose treatment. Start 2022-02-03 (actual); primary completion 2025-09-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MR Antagonist and LSD1
- Condition
- Hypertension
- Condition
- Mineralocorticoid Excess
- Intervention (Drug)
- Eplerenone
- Intervention (Drug)
- Amlodipine
- Lead sponsor
- Brigham and Women's Hospital
Record details
- Record id
cardio:ct-nct04840342- Content hash
d7d4ea2ffd234bb56c92e211b440baab726a873574db4f0a03bb1edf7ea51382